Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Jul 20.
Published in final edited form as: ACS Chem Biol. 2012 May 14;7(7):1232–1240. doi: 10.1021/cb300125k

A Sialyltransferase Mutant with Decreased Donor Hydrolysis and Reduced Sialidase Activities for Directly Sialylating Lewisx

Go Sugiarto a,, Kam Lau a,, Jingyao Qu a, Yanhong Li a, Sunghyuk Lim a, Shengmao Mu a, James B Ames a, Andrew J Fisher a,b,*, Xi Chen a,*
PMCID: PMC3521065  NIHMSID: NIHMS377686  PMID: 22583967

Abstract

Glycosyltransferases are important catalysts for enzymatic and chemoenzymatic synthesis of complex carbohydrates and glycoconjugates. The glycosylation efficiencies of wild-type glycosyltransferases vary considerably when different acceptor substrates were used. Using a multifunctional Pasteurella multocida sialyltransferase 1 (PmST1) as an example, we show here that the sugar nucleotide donor hydrolysis activity of glycosyltransferases contributes significantly to the low yield of glycosylation when a poor acceptor substrate is used. With a protein crystal structure-based rational design, we generated a single mutant (PmST1 M144D) with decreased donor hydrolysis activity without significantly affecting its α2–3-sialylation activity when a poor fucose-containing acceptor substrate was used. The single mutant also has a drastically decreased α2–3-sialidase activity. X-ray and NMR structural studies revealed that unlike the wild-type PmST1 which changes to a closed conformation once a donor binds, the M144D mutant structure adopts an open conformation even in the presence of the donor substrate. The PmST1 M144D mutant with decreased donor hydrolysis and reduced sialidase activity has been used as a powerful catalyst for efficient chemoenzymatic synthesis of complex sialyl Lewisx antigens containing different sialic acid forms. This work sheds new light on the effect of donor hydrolysis activity of glycosyltransferases on glycosyltransferase-catalyzed reactions and provides a novel strategy to improve glycosyltransferase substrate promiscuity by decreasing its donor hydrolysis activity.


Glycosyltransferase-catalyzed reactions have gained increasing attention and application for the synthesis of complex carbohydrates and glycoconjugates.13 Most mammalian glycosyltransferases suffer from no or low expression in E. coli systems and more restricted substrate specificity.4 In comparison, bacterial glycosyltransferases are generally easier to access using E. coli expression systems5 and have more promiscuous substrate flexibility.6,7 Nevertheless, despite the discovery of many bacterial glycosyltransferases which have promiscuities for both donor and acceptor substrates,6,7 the application of glycosyltransferases in the synthesis of carbohydrate-containing structures is limited by the availability and the substrate specificity of wild-type enzymes.810

For example, sialyltransferases, the key enzymes that catalyze the transfer of a sialic acid residue from cytidine 5′-monophosphate-sialic acid (CMP-sialic acid) to an acceptor, have been commonly used for the synthesis of sialic acid-containing structures.1116 Sialyl Lewisx [SLex, Siaα2–3Galβ1–4(Fucα1–3)GlcNAcβOR] is an important carbohydrate epitope involved in inflammation as well as adhesion and metastasis of cancer cells.17,18 It is a well-known tumor-associated carbohydrate antigen1923 and has been used as a candidate for cancer vaccine.21,24 The biosynthesis of SLex involves the formation of Siaα2–3Galβ1–4GlcNAcβOR catalyzed by an α2–3-sialyltransferase followed by an α1–3-fucosyltransferase-catalyzed fucosylation (Scheme S1). This biosynthetic sequence usually cannot be altered as common α2–3-sialyltransferases do not use fucose-containing Lewisx [Lex, Galβ1–4(Fucα1–3)GlcNAcβOR] as a substrate.25

As common terminal monosaccharides, sialic acids constitute a family of great structural diversity. So far, more than 50 structurally distinct sialic acid forms have been identified in nature.26 To obtain SLex with different sialic acid forms to elucidate the biological significance of naturally occurring sialic acid modifications, an efficient enzymatic approach is to use Lex [Galβ1–4(Fucα1–3)GlcNAcβOR] as a fucose-containing acceptor to add different sialic acid forms by a suitable α2–3-sialyltransferase.25 This process of introducing different forms of sialic acid onto the common fucosylated acceptor Lex in the last step has significant advantages compared to the normal SLex biosynthetic pathway in which fucosylation is the last glycosylation process (Scheme S1). It not only simplifies the synthetic scheme as a less number of reactions are needed, but also makes the purification process much easier as negatively charged SLex product is separated from neutral Lex oligosaccharide instead of separating both negatively charged oligosaccharides SLex and non-fucosylated sialosides if fucosylation occurs in the last step.

We and others have demonstrated that a myxoma virus α2–3-sialyltransferase can use Lex as an acceptor substrate for synthesizing SLex.25,27,28 Nevertheless, the low expression level of the enzyme in E. coli (<0.1 mg L−1 culture) limits its application in preparative and large-scale synthesis of SLex.25

We have previously shown that a multifunctional α2–3-sialyltransferase from Pasteurella multocida (PmST1)11,29,30 has a good expression level in E. coli (100 mg L−1 culture). It can use Lex as an acceptor for the synthesis of SLex but the yields are poor (<20%) in spite of different conditions tested.25 Our previous protein crystal structure-based mutagenesis studies led to the design of a PmST1 double mutant E271F/R313Y with a significantly (6333-fold) decreased sialidase activity when a non-fucose lactoside was used as an acceptor substrate.31 Nevertheless, the PmST1 E271F/R313Y does not efficiently sialylate fucose-containing oligosaccharides such as Lex. In this study, we show that the donor hydrolysis activity of PmST1 contributes significantly for the low yield sialylation of Lex. Based on protein x-ray crystal structure studies, a PmST1 mutant (PmST1 M144D) is successfully generated to decrease the donor hydrolysis activity without affecting its efficiency in sialylating Lex. The resulting PmST1 mutant also shows drastically decreased α2–3-sialidase activity and has been successfully applied in efficient sialylation of a poor fucose-containing Lex acceptor for the synthesis of complex and biologically important SLex oligosaccharides containing different sialic acid forms. Therefore, using PmST1 as the model system, we demonstrate that decreasing donor hydrolysis by site-directed mutagenesis may be a general approach to improve glycosyltransferase-catalyzed reactions when a poor glycosylation acceptor is used.

RESULTS AND DISCUSSION

Donor hydrolysis by PmST1 causes low yield sialylation of Lex

In order to understand why PmST1-catalyzed sialylation of Lex resulted in low yields, time course studies were carried out using a fluorescent-labeled Lex acceptor (4-methylumbelliferyl β-Lex or LexβMU) in a high performance liquid chromatography (HPLC) assay.25 As shown in Figure 1, PmST1-catalyzed sialylation of LexβMU (1 mM) using one equivalent of donor CMP-Neu5Ac reached a low yield (1.1–1.3%) plateau quickly within 2 min. Every additional dose of donor substrate CMP-Neu5Ac increased the product formation which always reached a plateau quickly. Monitoring the CMP-Neu5Ac consumption (% consumption numbers are shown in parentheses in Figure 1) in the reaction mixture by capillary electrophoresis studies confirmed a quick consumption of CMP-Neu5Ac. These indicated that donor (CMP-Neu5Ac) hydrolysis activity of PmST1, where water molecules compete with the poor Lex acceptor for the consumption of sugar nucleotide (CMP-Neu5Ac) donor of the sialyltransferase (Scheme S2), contributed significantly to the low yield of PmST1-catalyzed sialylation. In fact, donor hydrolysis has been observed for other glycosyltransferase-catalyzed reactions that lead to lower synthetic yields.32 The donor hydrolysis were observed frequently in co-crystallization of glycosyltransferases with a corresponding sugar nucleotide donor where its sugar component was usually cleaved off and only the hydrolyzed nucleotide was observed in the substrate binding pocket of the enzyme.29,33 Therefore, inert donor derivatives of glycosyltransferases have been commonly applied in the x-ray crystal structure studies of glycosyltransferases.30,33,34 Two recent papers discussed the donor hydrolysis activities of human blood group A and B glycosyltransferases (GTA and GTB) which are Mn2+-dependent35 and the UDP-Gal hydrolysis activity of GTB is increased in the presence of an acceptor substrate analog.36 Nevertheless, the effect of donor hydrolysis of glycosyltransferases on glycosylation processes has not been investigated in detail. In addition, no strategy has been reported for improving the yields of glycosyltransferase-catalyzed reactions by decreasing donor hydrolysis activity.

Figure 1.

Figure 1

HPLC-based time course studies of PmST1-catalyzed α2–3-sialylation of Lewisx trisaccharide (1 mM) with periodical addition of sialyltransferase donor CMP-Neu5Ac (indicated by arrows). As shown, the initial one equivalent of donor CMP-Neu5Ac resulted in a low yield (1.1%) product formation in 2 min. Every additional dose of donor substrate CMP-Neu5Ac (shown by arrows) increased the product formation which always reached a plateau quickly, indicating the quick consumption of the donor substrate. This was confirmed by capillary electrophoresis (CE) assays (numbers in parentheses present the % consumption of CMP-Neu5Ac). When a poor acceptor substrate such as Lewisx was used, quick hydrolysis of the donor substrate contributes significantly to the low yield formation of SLex in PmST1-catalyzed reaction.

Mechanism of PmST1-catalyzed CMP-Neu5Ac donor hydrolysis

1H NMR-based time course studies of the donor (CMP-Neu5Ac, 25 mM) hydrolysis activity of wild-type (WT) PmST1 (10.8 μg) (Figure 2) in either sodium tartrate buffer (10 mM, pH 5.5) or sodium phosphate buffer (20 mM, pH 8.0) indicate that both α-Neu5Ac and β-Neu5Ac were formed in CMP-Neu5Ac hydrolysis reactions. This conclusion is based on the comparison of Figure 2 with results of previously reported 1H NMR-based time course studies of the sialidase activity (Neu5AcαpNP, 20 mM, was used as the substrate) of WT PmST1 (65.0 μg) in the same sodium tartrate buffer (10 mM, pH 5.5) as Figure 2A.31 As shown previously, α-Neu5Ac was the initial product formed from α-linked sialoside (Neu5AcαpNP) catalyzed by the α2–3-sialidase activity of PmST1 in sodium tartrate buffer (10 mM, pH 5.5). The mutarotation of the α-Neu5Ac formed in the α2–3-sialidase reaction with sodium tartrate buffer (10 mM, pH 5.5) to β-Neu5Ac took more than 20 minutes and α-Neu5Ac was the predominant form in reaction mixtures with at least up to 2 hours of reaction time.31 This slow mutarotation process is most likely due to the spontaneous mutarotation of α-Neu5Ac to β-Neu5Ac which is a predominant form (>90%)37,38 at equilibrium and not due to the activity of a mutarotase.39 In contrast, both α-Neu5Ac and β-Neu5Ac were observed in 5 min in the PmST1-catalyzed CMP-Neu5Ac hydrolysis reaction. Due to the same buffer (sodium tartrate buffer, 10 mM, pH 5.5) condition and a less amount of PmST1 (10.8 μg) used in the CMP-Neu5Ac hydrolysis reaction (comparing to 65.0 μg PmST1 used in the sialidase reaction), the mutarotation between α-Neu5Ac and β-Neu5Ac will not be faster than in the sialidase reaction and the only explanation is that both α-Neu5Ac and β-Neu5Ac are formed in PmST1-catalyzed donor hydrolysis reaction. Comparison of the integration of H3eqαNeu5Ac peaks around 2.90 ppm and H3eqβNeu5Ac peaks around 2.38 ppm provides ratios of 1:1.52, 1:1.82, 1:2.86, 1:3.33 and 1:5.26 for reaction mixtures at 5, 10, 15, 35, and 70 min, respectively. The percentage increase of the β-Neu5Ac product with the increase of reaction time may be contributed at least partially by spontaneous mutarotation of α-Neu5Ac to β-Neu5Ac.

Figure 2.

Figure 2

Time course studies of PmST1 donor (CMP-Neu5Ac) hydrolysis by 1H NMR (600 MHz) analysis in A) sodium tartrate buffer (10 mM, pH 5.5) or B) sodium phosphate buffer (20 mM, pH 8.0) containing CMP-Neu5Ac (25 mM) and PmST1 (10.8 μg). The initial observation of both α-Neu5Ac and β-Neu5Ac indicates a combination of inverting and retaining mechanisms for PmST1-catalyzed CMP-Neu5Ac hydrolysis reaction. Ratios of peak integration of H3eqαNeu5Ac peaks (~2.90 ppm) and H3eqβNeu5Ac peaks (~2.38 ppm) for the PmST1-catalyzed CMP-Neu5Ac hydrolysis reaction in sodium tartrate buffer (10 mM, pH 5.5) are shown below the NMR spectra in Figure 2A.

The observation of the formation of both α-Neu5Ac and β-Neu5Ac in PmST1-catalyzed CMP-Neu5Ac hydrolysis reaction was a surprise as it indicates that the donor hydrolysis can undergo two different paths. One is the formation of α-Neu5Ac from β-linked Neu5Ac in CMP-Neu5Ac which goes through an inverting process similar to the inverting mechanism of α2–3-sialyltransferase reaction catalyzed by the same enzyme in which an α2–3-sialyl linkage is formed from β-linked Neu5Ac in the CMP-Neu5Ac donor. In this process, a water molecule competes with, most likely by replacement of, an acceptor molecule for the same donor substrate in PmST1-catalyzed reaction. The other is the formation of β-Neu5Ac from β-linked Neu5Ac in CMP-Neu5Ac which undergoes a retaining process and is opposite to the inverting mechanism of α2–3-sialyltransferase reaction. In this process, the water and the acceptor may occupy different binding pockets, and therefore the amino acid residues in the substrate binding pocket may play different roles in donor hydrolysis and α2–3-sialylation reactions.

PmST1 crystal structural analysis

Examining the co-crystal structures of PmST1 with a donor analog CMP-3F(axial)-Neu5Ac in the presence (PDB ID# 2IHZ) and absence (PDB ID# 2IHJ) of an acceptor (lactose) indicated that Asp141 and His311 are in close proximity to the donor analog.29,30 Previous structural and kinetic studies30 indicated that Asp141 serves as a general base to activate the C3′-hydroxyl group in the lactose acceptor for PmST1-catalyzed α2–3-sialylation with a direct displacement mechanism involving an oxocarbenium ion-like transition state that leads to the overall inversion of the configuration of the anomeric center of the sialic acid. His311 was believed to act as a general acid that helps to stabilize the CMP leaving group. The potential roles were supported by previously reported mutagenesis studies which showed that H311A mutation resulted in 28-fold decrease in the efficiency of α2–3-sialyltransferase activity while D141A mutation decreased the α2–3-sialyltransferase activity by more than 20,000-fold.30

Asp141 and His311 influence PmST1 donor hydrolysis activity

The important roles of Asp141 and His311 in the CMP-Neu5Ac donor hydrolysis activity of PmST1 were demonstrated by the kinetic studies of previously generated D141A and H311A mutants.30 As shown in Table 1, D141A mutation decreased the efficiency of CMP-Neu5Ac hydrolysis activity of PmST1 by 1,000-fold mainly due to the decrease in the turnover number. H311A mutation also decreased the CMP-Neu5Ac hydrolysis activity by 16-fold, mainly contributed by a decreased turnover number without affecting the binding affinity significantly. The data indicate that Asp141 plays a more important function than His311 in the donor hydrolysis activity of PmST1.

Table 1.

Apparent kinetics of the CMP-Neu5Ac hydrolysis activity of WT PmST1 and mutants.

Km (mM) kcat (s−1) kcat/Km (s−1 mM−1)
WT 1.5 ± 0.2 27 ± 1 18
a D141A 1.4 ± 0.2 (2.5 ± 0.1) × 10−2 1.8 × 10−2
a H311A 1.8 ± 0.2 2.1 ± 0.1 1.1
M144D 7.3 ± 0.5 6.5 ± 0.1 0.89
M144H 13 ± 3 71 ± 6 5.5
a

PmST1 D141A and H311A mutants were generated previously.30

PmST1 mutants with decreased CMP-Neu5Ac hydrolysis activity

To decrease the CMP-Neu5Ac hydrolysis activity of PmST1 and to improve its application in α2–3-sialylation of fucose-containing Lex, two amino acid residues Met144 and Ala35 that are in close proximity to Asp141 shown in the PmST1 ternary crystal structure with sialyltransferase donor analog and acceptor30 were chosen for site-directed mutagenesis studies. The hypothesis was that changing a hydrophobic residue to a charged Asp or His residue near Asp141, an important amino acid residue for both CMP-Neu5Ac hydrolysis and α2–3-sialyltransferase activities, may alter the PmST1 activities by shifting the pKa or the position of Asp141. Initial tests on their α2–3-sialyltransferase activity using Lex as an acceptor indicated that both A35D and A35H PmST1 mutants were inactive. In comparison, both M144D and M144H were active while M144D mutant provided better yields than M144H mutant for the formation of SLex.

As shown in Table 1, both M144D and M144H mutations decreased the efficiency of donor hydrolysis with varied degrees. M144D mutation decreased the efficiency of donor hydrolysis 20-fold due to a 4.9-fold increase of the Km value and a 4.2-fold decrease of the kcat value. M144H mutation caused a less significant 3.3-fold decrease in the efficiency of donor hydrolysis due to a significant 8.7-fold increase in the Km value which is offset by a 2.6-fold increase in the kcat value.

The α2–3-sialyltransferase activities of PmST1 mutants

M144D and M144H mutations also have different effects on the α2–3-sialyltransferase activity of the enzyme. As shown in Table 2, when a good sialyltransferase acceptor 4-methylumbelliferyl β-lactoside (LacβMU) was used, the M144D mutation decreased the α2–3-sialyltransferase activity 18-fold due to a 9-fold increase of Km value and a 2-fold decrease of kcat value. Interestingly, when a poor sialyltransferase acceptor LexβMU was used, the M144D mutation did not change the efficiency of the α2–3-sialyltransferase activity of PmST1 significantly. In comparison, M144H mutation only decreased the α2–3-sialyltransferase activity weakly (1.3-fold) when LacβMU was used as an acceptor and increased the efficiency of α2–3-sialyltransferase activity by 2.6-fold when LexβMU was used as an acceptor. These discrepancies may be due to the stronger acidity of the amino acid side chain in the aspartic acid than that in the histidine.

Table 2.

Apparent kinetics of the α2–3-sialyltransferase activity of WT PmST1 and mutants.

Km (MM) kcat (s−1) kcat/Km (s−1 mM−1)
WT M144D M144H WT M144D M144H WT M144D M144H
LacβMU a1.4 12±1 0.79±0.04 a47 22±1 21 ± 1 a34 1.9 27
b CMP-Neu5Ac a0.44 0.30±0.05 0.81±0.06 a32 1.9±0.1 21 ± 1 a73 6.1 27
LexβMU 17±2 13±2 8.1±0.9 6.7±0.3 4.0±0.2 8.4±0.3 0.38 0.32 1.0
c CMP-Neu5Ac 0.39±0.03 2.1±0.1 0.4 ±0.05 0.55±0.01 0.59±0.01 0.93±0.02 1.4 0.28 2.2
a

Data are from Ref. 11,

b

With LacβMU,

c

With LexβMU.

PmST1 M144D mutant has a drastically decreased α2–3-sialidase activity

To our delight, M144D and M144H mutations also decreased the α2–3-sialidase activity of PmST1 drastically by 5588- and 594-fold respectively when Neu5Acα2–3LacβMU was used as the sialidase substrate (Table 3). Interestingly, while the PmST1 M144D mutant showed no sialidase activity when Neu5Acα2–3LexβMU was used as the substrate, PmST1 M144H has increased sialidase activity compared to the WT PmST1 using the SLex substrate. For example, the PmST1 M144H mutant cleaved 10.0%, 24.5%, and 34.0% of Neu5Ac from Neu5Acα2–3LexβMU in 1 hr, 6 hr, and 20 hr, respectively. In comparison, WT PmST1 removed 2.0%, 7.0%, and 7.5% of Neu5Ac from Neu5Acα2–3LexβMU under similar reaction conditions. The drastically decreased α2–3-sialidase activity by M144D mutation allows the potential application of the PmST1 M144D mutant in sialylation of glycoconjugates containing terminal galactoside or Lex where the decreased α2–3-sialidase activity has the most advantages as these reactions are challenging for prompt monitoring.31

Table 3.

Apparent kinetics of the α2–3-sialidase activity of WT PmST1, M144D, and M144H mutants using Neu5Acα2–3LacβMU as the sialidase substrate.

Km (mM) kcat (s−1) kcat/Km (s−1 mM−1)
a WT a24 a2.3 × 102 a9.5
M144D 20 ± 2 (3.5 ± 0.1) × 10−2 1.7 × 10−3
M144H 1.7 ± 0.3 (2.7 ± 0.2) × 10−2 1.6 × 10−2
a

Data are from Ref. 11

PmST1 M144D mutant has a similar expression level as the WT PmST1

The PmST1 M144D mutation did not change the enzyme expression level in E. coli. About 98 mg of C-His6-tagged PmST1 M144D protein can be routinely purified from one liter of E. coli cell culture using Ni2+-affinity column (Figure S1). This expression level is very similar to that (100 mg) of the WT PmST111 and allows the application of the mutant in preparative and large-scale synthesis of SLex antigens.

X-Ray crystal structure of PmST1 M144D mutant

The structure of the PmST1 M144D mutant with CMP-3F(axial)-Neu5Ac was determined to 1.45Å resolution with Rfactor and Rfree values of 18.7% and 21.5% respectively (Table S1). To our surprise, the structure resides in the open conformation similar to the wild-type structure with no substrate (rmsd of 0.50 Å for 385 equivalent α-carbons).29 However, the M144D structure contains well-ordered electron density in the active site that clearly defines the CMP nucleotide. The sialic acid moiety is disordered, likely due to dynamics and/or multiple conformations in the open state of the enzyme. In the M144D structure, the CMP moiety does not bind as deeply into the pocket of the active site as the WT PmST1. The base and ribose are situated about 1.5 and 2.0 Å respectively, farther out of the active site compared to the WT PmST1 (Figure 3). In the wild-type structure, Glu338 forms bidentate hydrogen bond interactions with both the 2′ and 3′ OH of the CMP ribose. In the M144D structure, an ordered water molecule mediates the interaction between the ribose and Glu338 (Figure 3). The more shallow binding of the donor nucleotide in the M144D structure does not pull down the β-strand and the ensuing loop that contains Trp270. In comparison, in the wild-type enzyme, donor-nucleotide binding pulls down a β-strand causing Trp270 to pop out of the C-terminal domain, where it helps define the acceptor binding site in the sialyltransferase reaction.30

Figure 3.

Figure 3

Structural comparison between WT PmST1 and M144D mutant with bound CMP donor. (A) Overall structure of WT PmST1 with CMP bound (white), aligned with the C-terminal domain of the M144D mutant (cyan) also with CMP bound (space filled atoms). (B), Stereo view of the superposition near the active site. WT PmST1 is shown in white with bound CMP-3F(a)-Neu5Ac (sticks with white carbon bonds) and lactose acceptor (sticks with grey carbon bonds). The M144D mutant in shown in cyan with CMP bound (sticks with cyan carbon bonds). (C) Active site of the ternary crystal structure of PmST1 (PDB 1D: 21HZ) with bound CMP-3F(axial)-Neu5Ac and lactose. The mutation site M144 is underlined.

NMR analysis of PmST1 M144D mutant

The open conformation of the M144D mutant bound to donor nucleotide is not a crystallization artifact. Solution NMR studies corroborate the open conformation of the mutant with bound donor. 15N-1H HSQC NMR spectra of both WT and M144D mutant (apo and CMP-bound forms) all exhibited the expected number of dispersed peaks with uniform intensities (Figure 4), indicating that the protein adopts a stable three-dimensional fold, consistent with the x-ray crystal structures. The peaks in the HSQC spectra represent the main chain amide groups that serve as fingerprints of the overall main chain conformation. The HSQC spectra of apo-WT, apo-M144D and CMP-bound M144D all exhibit a similar pattern of peaks (Figure 4, see red circles), consistent with all three adopting an open conformation in solution like that observed in the crystal structures. By contrast, the HSQC spectrum of CMP-bound WT has a distinct pattern of peaks not observed in the other three spectra, suggesting that CMP-bound PmST1 adopts a distinct closed conformation in solution like that observed in the crystal structure.

Figure 4.

Figure 4

15N-1H HSQC NMR spectra of 15N-labeled PmST1 (WT versus M144D and apo versus CMP-bound).

It is unclear whether the open conformation of PmST1 M144D, which may be able to accommodate a bigger acceptor such as Lex, is responsible for its decreased donor hydrolysis activity and similar activity in sialylation of Lex. It is also possible that the closed conformation of PmST1 M144D mutant may still exist, but at a much lower abundance. The closed conformation may be responsible for sialylation and/or donor hydrolysis as the WT PmST1 has similar efficiency as the M144D mutant in sialylating Lex. The M144D mutation may cause a weaker interaction of the active site (Asp141 and/or His311) with water and a better binding of the enzyme with LexβMU as supported by the Km data (M144D, 13±2 mM; WT PmST1, 17±2 mM). We are trying to get co-crystal structures of WT PmST1 or the M144D mutant with CMP-3F(axial)Neu5Ac and Lex to solve this puzzle.

PmST1 M144D mutant is more efficient than M144H mutant in sialylating Lex

Overall, the M144D mutation decreased the undesired CMP-Neu5Ac hydrolysis activity significantly (20-fold) without appreciably changing the efficiency of the α2–3-sialyltransferase activity when Lex was used as an acceptor. As a result, M144D showed an overall improved activity in sialylation of Lex for the formation of sialyl Lex (SLex) structures. In comparison, M144H mutant which has a 3.3-fold decreased CMP-Neu5Ac hydrolysis activity and 2.6-fold increased α2–3-sialyltransferase activity using Lex as an acceptor was less effective in direct sialylating Lex.

Synthesis of SLex containing diverse sialic acid forms using PmST1 M144D mutant

The application of the PmST1 M144D mutant obtained by protein structure-based rational design in the synthesis of SLex containing diverse naturally occurring and non-natural sialic acid forms was demonstrated using an efficient one-pot three-enzyme chemoenzymatic synthetic system (Scheme 1). The system contained PmST1 M144D mutant, an Neisseria meningitidis CMP-sialic acid synthetase (NmCSS),40 and a Pasteurella multocida sialic acid aldolase.41 N-Acetylmannosamine (ManNAc), mannose, and their derivatives11,15 were used for in situ synthesis of CMP-sialic acids and derivatives. Lex trisaccharide used as the sialyltransferase acceptor was synthesized using a one-pot two-enzyme system containing a bifunctional L-fucokinase/GDP-fucose pyrophosphorylase (FKP) cloned from Bacteroides fragilis42 and a recombinant Helicobacter pylori α1–3-fucosyltransferase as shown previously.25 As shown in Scheme 1, SLex tetrasaccharides containing natural sialic acid forms including N-acetylneuraminc acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), 2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid (Kdn), as well as 9-O-acetylated Neu5Ac and Neu5Gc were obtained in excellent (85–93%) to good yields (62–64%). The relatively lower yields for the synthesis of SLex containing the 9-O-acetyl sialic acid forms were due to the de-O-acetylation process leading to the formation of non-O-acetylated SLex oligosaccharides. In addition, SLex containing non-natural sialic acid forms including those with an N-azidoacetyl group or an azido group at C-5 or a C-9 azido group were also successfully obtained in excellent yields (84–91%). We would like to point out that the synthesis of SLex containing 9-O-acetyl sialic acid forms was not possible previously by fucosyltransferase-catalyzed fucosylation of sialyl LacNAc due to easy loss of the 9-O-acetyl group in longer reaction time or purification process. The efficiency of the WT PmST1 for sialylation of Lex was too low to achieve reasonable yields.

Scheme 1.

Scheme 1

One-pot three-enzyme synthesis of sialyl LexβProN3 (SLexβProN3) containing different forms of sialic acids from LexβProN3. Aldolase, Pasteurella multocida sialic acid aldolase; NmCSS, Neisseria meningitidis CMP-sialic acid synthetase.

Conclusion

In conclusion, we show here that the donor hydrolysis activity contributes significantly to the low yield synthesis of sialyl Lex catalyzed by a multifunctional Pasteurella multocida sialyltransferase (PmST1) when a poor acceptor Lex is used. We also show that protein x-ray crystal structure-based site-directed mutagenesis can be used as an effective strategy to generate a sialyltransferase single mutant (M144D) with decreased donor hydrolysis activity without affecting the activity in sialylating Lex. The PmST1 M144D mutant retains a high expressing level (98 mg L−1 culture) and the donor substrate promiscuity of the wild-type enzyme. It is a powerful catalyst for synthesizing SLex containing different sialic acid forms which are unable or difficult to obtain by any other synthetic or isolation strategies. The study presented here sheds new light on the effect of donor hydrolysis in glycosyltransferase-catalyzed reactions and supplies a new powerful catalyst for efficient chemoenzymatic synthesis of important SLex structures. The study also opens a new revenue by decreasing donor hydrolysis activity of glycosyltransferases for improving the efficiency of glycosyltransferase-catalyzed reactions, especially when poor acceptor substrates are used. Although a specific strategy is unclear at the moment, a general approach to achieve this is by mutating the amino acid residues that are located near the key catalytic base of glycosyltransferases. It will also be interesting to characterize the donor hydrolysis activities of other glycosyltransferases and their mutants810 to see whether changes in donor hydrolysis contribute to broadening the substrate specificity by mutagenesis.

MATERIALS AND METHODS

Site-directed mutagenesis, expression and purification of PmST1 mutants

Site-directed mutagenesis was performed using the QuikChange multi-site-directed mutagenesis kit from Stratagene according to the manufacturer’s protocol. The primers used were 5′ AATCTTTATGACGATGGCTCAGATGAATATGTTGATTTAGAAAAAG 3′ for M144D; 5′ AATCTTTATGACGATGGCTCACATGAATATGTTGATTTAGAAAAAG 3′ for M144H; 5′ ATCACGCTGTATTTAGATCCTGATTCCTTACCGGCATTAAATCAG 3′ for A35D; and 5′ ATCACGCTGTATTTAGATCCTCATTCCTTACCGGCATTAAATCAG 3′ for A35H. The expression and purification of the mutants were performed as previously described for the WT PmST1.11,29

Kinetics of the donor hydrolysis activity of PmST1 and mutants by capillary electrophoresis analysis

The reactions were carried out in duplicate in a total volume of 10 μL at 37 °C for 15 min (WT), 40 min (D141A), 20 min (H311A), or 15 min (M144D and M144H) in Tris-HCl buffer (200 mM, pH 8.5) containing CMP-Neu5Ac (1, 2, 5, 10, 20 and 40 mM) and an enzyme (WT, 4 μg mL−1; D141A, 1500 μg mL−1; H311A, 40 μg mL−1; M144D, 39 μg mL−1; M144H, 5 μg mL−1). The reactions were stopped by adding 10 μL of pre-chilled ethanol. The mixtures were incubated on ice for 30 min and centrifuged at 13,000 rpm for 5 min. The supernatants were diluted with borate buffer (25 mM, pH 9.5) and aliquotes of 5 μL each were injected to a Beckman Coulter P/ACE MDQ Capillary Electrophoresis system equipped with a capillary (60 cm × 75 μm i.d.) and monitored at 254 nm. The apparent kinetic parameters were obtained by fitting the experimental data (the average values of duplicate assay results) into the Michaelis–Menten equation using Grafit 5.0.

Kinetics of the α2–3-sialyltransferase activity of PmST1 mutants by HPLC analysis

With LacβMU as the acceptor substrate, the reactions were performed in duplicate at 37 °C for 10 min (M144D) or 4 min (M144H) in a reaction mixture (10 μL) containing Tris-HCl (100 mM, pH 8.5), an enzyme (5 μg mL−1), and different concentrations (0.2, 0.5, 1.0, 2.0, and 5.0 mM) of LacβMU with a fixed concentration (1 mM) of CMP-Neu5Ac or different concentrations (0.2, 0.5, 1.0, 2.0, 5.0, and 10.0 mM) of CMP-Neu5Ac with a fixed concentration (1 mM) of LacβMU. With LexβMU as the acceptor substrate, the reactions were carried out in duplicate at 37 °C for 9 min (M144D) or 10 min (M144H) in a reaction mixture (10 μL) containing CAPSO (100 mM, pH 9.5), an enzyme (M144D, 39 μg mL−1 or M144H, 5 μg mL−1), and various concentrations of LexβMU (1.0, 5.0, 10.0, 15.0, 25.0, and 35.0 mM) with a fixed concentration (1 mM) of CMP-Neu5Ac or various concentrations (0.2, 0.5, 1.0, 2.0, 5.0, 10.0, 20.0, and 40.0 mM) of CMP-Neu5Ac with a fixed concentration (1 mM) of LexβMU. Reactions were stopped by adding 10 μL of pre-chilled ethanol. The mixtures were incubated on ice for 30 min and centrifuged at 13,000 rpm for 5 min. The supernatants were diluted with 25% acetonitrile and kept on ice until aliquots of 8 μL were injected and analyzed by the Shimadzu LC-6AD system equipped with a membrane on-line degasser, a temperature control unit, and a fluorescence detector (Shimadzu RF-10AXL). A reverse-phase Premier C18 column (250 × 4.6 mm i.d., 5 μm particle size, Shimadzu) protected with a C18 guard column cartridge was used. The mobile phase was 25% acetonitrile. The fluorophore (MU)-labeled compounds were detected by excitation at 325 nm and emission at 372 nm.11,43 The apparent kinetic parameters were obtained by fitting the experimental data (the average values of duplicate assay results) into the Michaelis–Menten equation using Grafit 5.0.

Kinetics of the α2–3-sialidase activity of PmST1 mutants

The reactions were performed in duplicate in a total volume of 10 μL at 37 °C for 60 min (M144D) or 15 min (M144H) in MES buffer (100 mM, pH 5.5) containing Neu5Acα2–3LacβMU (0.4, 1, 2, 4, 10, 20, 40 and 60 mM) and an enzyme (M144H, 1.36 mg mL−1 or M144D, 1.05 mg mL−1). Sample treatment after the reaction and analysis were carried out by HPLC similar to that described above for the α2–3-sialyltransferase assays.

The α2–3-sialidase activity assays of PmST1 and mutants

The reactions were carried out in duplicate in a total volume of 10 μL at 37 °C for 20 hr in MES buffer (100 mM, pH 5.5) containing Neu5Acα2–3LexβMU (1 mM) and an enzyme (4 mg mL−1). Aliquots of 1 μL were withdrawn at 1 hr, 6 hr and 20 hr, and analyzed by HPLC as described above for the α2–3-sialyltransferase assays.

Supplementary Material

1_si_001

Acknowledgments

This work was supported by NIH grants R01GM076360 and R01HD065122 (to X. C.); and R01EY012347 (to J. B. A.). X. C. is an Alfred P. Sloan Research Fellow, a Camille Dreyfus Teacher-Scholar, and a UC-Davis Chancellor’s Fellow. Portions of this research were carried out at the Stanford Synchrotron Radiation Lightsource (SSRL), a Directorate of SLAC National Accelerator Laboratory and an Office of Science User Facility operated for the U.S. Department of Energy Office of Science by Stanford University. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Center for Research Resources, Biomedical Technology Program (P41RR001209), and the National Institute of General Medical Sciences.

Footnotes

Accession Codes

The structure of PmST1 M144D mutant in complex with CMP-3F(a)-Neu5Ac was deposited with a PDB ID code 3S44.

Supporting Information Available: This material is available free of charge via the Internet at http://pubs.acs.org.

References

  • 1.Koeller KM, Wong CH. Enzymes for chemical synthesis. Nature. 2001;409:232–240. doi: 10.1038/35051706. [DOI] [PubMed] [Google Scholar]
  • 2.Koeller KM, Wong CH. Synthesis of complex carbohydrates and glycoconjugates: Enzyme-based and programmable one-pot strategies. Chem Rev. 2000;100:4465–4493. doi: 10.1021/cr990297n. [DOI] [PubMed] [Google Scholar]
  • 3.Wymer N, Toone EJ. Enzyme-catalyzed synthesis of carbohydrates. Curr Opin Chem Biol. 2000;4:110–119. doi: 10.1016/s1367-5931(99)00061-7. [DOI] [PubMed] [Google Scholar]
  • 4.Weijers CA, Franssen MC, Visser GM. Glycosyltransferase-catalyzed synthesis of bioactive oligosaccharides. Biotechnol Adv. 2008;26:436–456. doi: 10.1016/j.biotechadv.2008.05.001. [DOI] [PubMed] [Google Scholar]
  • 5.Wakarchuk WW, Cunningham A, Watson DC, Young NM. Role of paired basic residues in the expression of active recombinant galactosyltransferases from the bacterial pathogen Neisseria meningitidis. Protein Eng. 1998;11:295–302. doi: 10.1093/protein/11.4.295. [DOI] [PubMed] [Google Scholar]
  • 6.Gilbert M, Bayer R, Cunningham AM, DeFrees S, Gao Y, Watson DC, Young NM, Wakarchuk WW. The synthesis of sialylated oligosaccharides using a CMP-Neu5Ac synthetase/sialyltransferase fusion. Nat Biotechnol. 1998;16:769–772. doi: 10.1038/nbt0898-769. [DOI] [PubMed] [Google Scholar]
  • 7.Gilbert M, Cunningham AM, Watson DC, Martin A, Richards JC, Wakarchuk WW. Characterization of a recombinant Neisseria meningitidis alpha-2,3-sialyltransferase and its acceptor specificity. Eur J Biochem. 1997;249:187–194. doi: 10.1111/j.1432-1033.1997.t01-1-00187.x. [DOI] [PubMed] [Google Scholar]
  • 8.Williams GJ, Zhang C, Thorson JS. Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution. Nat Chem Biol. 2007;3:657–662. doi: 10.1038/nchembio.2007.28. [DOI] [PubMed] [Google Scholar]
  • 9.Gantt RW, Goff RD, Williams GJ, Thorson JS. probing the aglycon promiscuity of an engineered glycosyltransferase. Angew Chem Int Ed. 2008;47:8889–8892. doi: 10.1002/anie.200803508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Yang G, Rich JR, Gilbert M, Wakarchuk WW, Feng Y, Withers SG. Fluorescence activated cell sorting as a general ultra-high-throughput screening method for directed evolution of glycosyltransferases. J Am Chem Soc. 2010;132:10570–10577. doi: 10.1021/ja104167y. [DOI] [PubMed] [Google Scholar]
  • 11.Yu H, Chokhawala H, Karpel R, Yu H, Wu B, Zhang J, Zhang Y, Jia Q, Chen X. A multifunctional Pasteurella multocida sialyltransferase: a powerful tool for the synthesis of sialoside libraries. J Am Chem Soc. 2005;127:17618–17619. doi: 10.1021/ja0561690. [DOI] [PubMed] [Google Scholar]
  • 12.Chokhawala HA, Huang S, Lau K, Yu H, Cheng J, Thon V, Hurtado-Ziola N, Guerrero JA, Varki A, Chen X. Combinatorial chemoenzymatic synthesis and high-throughput screening of sialosides. ACS Chem Biol. 2008;3:567–576. doi: 10.1021/cb800127n. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Cao H, Li Y, Lau K, Muthana S, Yu H, Cheng J, Chokhawala HA, Sugiarto G, Zhang L, Chen X. Sialidase substrate specificity studies using chemoenzymatically synthesized sialosides containing C5-modified sialic acids. Org Biomol Chem. 2009;7:5137–5145. doi: 10.1039/b916305k. [DOI] [PubMed] [Google Scholar]
  • 14.Morley TJ, Withers SG. Chemoenzymatic synthesis and enzymatic analysis of 8-modified cytidine monophosphate-sialic acid and sialyl lactose derivatives. J Am Chem Soc. 2010;132:9430–9437. doi: 10.1021/ja102644a. [DOI] [PubMed] [Google Scholar]
  • 15.Yu H, Huang S, Chokhawala H, Sun M, Zheng H, Chen X. Highly efficient chemoenzymatic synthesis of naturally occurring and non-natural alpha-2,6-linked sialosides: a P. damsela alpha-2,6-sialyltransferase with extremely flexible donor-substrate specificity. Angew Chem Int Ed. 2006;45:3938–3944. doi: 10.1002/anie.200600572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Drouillard S, Mine T, Kajiwara H, Yamamoto T, Samain E. Efficient synthesis of 6′-sialyllactose, 6,6′-disialyllactose, and 6′-KDO-lactose by metabolically engineered E. coli expressing a multifunctional sialyltransferase from the Photobacterium sp JT-ISH-224. Carbohydr Res. 2010;345:1394–1399. doi: 10.1016/j.carres.2010.02.018. [DOI] [PubMed] [Google Scholar]
  • 17.Ugorski M, Laskowska A. Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol. 2002;49:303–311. [PubMed] [Google Scholar]
  • 18.Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol. 2004;22:129–156. doi: 10.1146/annurev.immunol.21.090501.080131. [DOI] [PubMed] [Google Scholar]
  • 19.Sell S. Cancer-associated carbohydrates identified by monoclonal antibodies. Hum Pathol. 1990;21:1003–1019. doi: 10.1016/0046-8177(90)90250-9. [DOI] [PubMed] [Google Scholar]
  • 20.Dube DH, Bertozzi CR. Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev. 2005;4:477–488. doi: 10.1038/nrd1751. [DOI] [PubMed] [Google Scholar]
  • 21.Hakomori S. Possible functions of tumor-associated carbohydrate antigens. Curr Opin Immunol. 1991;3:646–653. doi: 10.1016/0952-7915(91)90091-e. [DOI] [PubMed] [Google Scholar]
  • 22.Itzkowitz SH, Yuan M, Fukushi Y, Palekar A, Phelps PC, Shamsuddin AM, Trump BF, Hakomori S, Kim YS. Lewisx- and sialylated Lewisx-related antigen expression in human malignant and nonmalignant colonic tissues. Cancer Res. 1986;46:2627–2632. [PubMed] [Google Scholar]
  • 23.Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, Kannagi R. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 1993;53:354–361. [PubMed] [Google Scholar]
  • 24.Ravindranath MH, Kelley MC, Jones RC, Amiri AA, Bauer PM, Morton DL. Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Int J Cancer. 1998;75:117–124. doi: 10.1002/(sici)1097-0215(19980105)75:1<117::aid-ijc18>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  • 25.Sugiarto G, Lau K, Yu H, Vuong S, Thon V, Li Y, Huang S, Chen X. Cloning and characterization of a viral α2–3-sialyltransferase (vST3Gal-I) for the synthesis of sialyl Lewisx. Glycobiology. 2011;21:387–396. doi: 10.1093/glycob/cwq172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Chen X, Varki A. Advances in the biology and chemistry of sialic acids. ACS Chem Biol. 2010;5:163–176. doi: 10.1021/cb900266r. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Jackson RJ, Hall DF, Kerr PJ. Myxoma virus encodes an alpha2,3-sialyltransferase that enhances virulence. J Virol. 1999;73:2376–2384. doi: 10.1128/jvi.73.3.2376-2384.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sujino K, Uchiyama T, Hindsgaul O, Seto NOL, Wakarchuk W, Palcic MM. Enzymatic synthesis of oligosaccharide analogues: Evaluation of UDP-Gal analogues as donors for three retaining R-galactosyltransferases. J Am Chem Soc. 2000;122:1261–1269. [Google Scholar]
  • 29.Ni L, Sun M, Yu H, Chokhawala H, Chen X, Fisher AJ. Cytidine 5′-monophosphate (CMP)-induced structural changes in a multifunctional sialyltransferase from Pasteurella multocida. Biochemistry. 2006;45:2139–2148. doi: 10.1021/bi0524013. [DOI] [PubMed] [Google Scholar]
  • 30.Ni L, Chokhawala HA, Cao H, Henning R, Ng L, Huang S, Yu H, Chen X, Fisher AJ. Crystal structures of Pasteurella multocida sialyltransferase complexes with acceptor and donor analogues reveal substrate binding sites and catalytic mechanism. Biochemistry. 2007;46:6288–6298. doi: 10.1021/bi700346w. [DOI] [PubMed] [Google Scholar]
  • 31.Sugiarto G, Lau K, Li Y, Khedri Z, Yu H, Le DT, Chen X. Decreasing the sialidase activity of multifunctional Pasteurella multocida α2–3-sialyltransferase 1 (PmST1) by site-directed mutagenesis. Mol Biosyst. 2011;7:3021–3027. doi: 10.1039/c1mb05182b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Zhang L, Lau K, Cheng J, Yu H, Li Y, Sugiarto G, Huang S, Ding L, Thon V, Wang PG, Chen X. Helicobacter hepaticus Hh0072 gene encodes a novel alpha1–3-fucosyltransferase belonging to CAZy GT11 family. Glycobiology. 20:1077–1088. doi: 10.1093/glycob/cwq068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Chiu CP, Watts AG, Lairson LL, Gilbert M, Lim D, Wakarchuk WW, Withers SG, Strynadka NC. Structural analysis of the sialyltransferase CstII from Campylobacter jejuni in complex with a substrate analog. Nat Struct Mol Biol. 2004;11:163–170. doi: 10.1038/nsmb720. [DOI] [PubMed] [Google Scholar]
  • 34.Chiu CP, Lairson LL, Gilbert M, Wakarchuk WW, Withers SG, Strynadka NC. Structural analysis of the alpha-2,3-sialyltransferase Cst-I from Campylobacter jejuni in apo and substrate-analogue bound forms. Biochemistry. 2007;46:7196–7204. doi: 10.1021/bi602543d. [DOI] [PubMed] [Google Scholar]
  • 35.Soya N, Shoemaker GK, Palcic MM, Klassen JS. Comparative study of substrate and product binding to the human ABO(H) blood group glycosyltransferses. Glycobiology. 2009;19:1224–1234. doi: 10.1093/glycob/cwp114. [DOI] [PubMed] [Google Scholar]
  • 36.Sindhuwinata N, Munoz E, Munoz FJ, Palcic MM, Peters H, Peters T. Binding of an acceptor substrate analog enhances the enzymatic activity of human blood group B galactosyltransferase. Glycobiology. 2010;20:718–723. doi: 10.1093/glycob/cwq019. [DOI] [PubMed] [Google Scholar]
  • 37.Moustafa I, Connaris H, Taylor M, Zaitsev V, Wilson JC, Kiefel MJ, von Itzstein M, Taylor G. Sialic acid recognition by Vibrio cholerae neuraminidase. J Biol Chem. 2004;279:40819–40826. doi: 10.1074/jbc.M404965200. [DOI] [PubMed] [Google Scholar]
  • 38.Jaques LW, Brown EB, Barrett JM, Brey WS, Jr, Weltner W., Jr Sialic acid. A calcium-binding carbohydrate. J Biol Chem. 1977;252:4533–4538. [PubMed] [Google Scholar]
  • 39.Severi E, Muller A, Potts JR, Leech A, Williamson D, Wilson KS, Thomas GH. Sialic acid mutarotation is catalyzed by the Escherichia coli beta-propeller protein YjhT. J Biol Chem. 2008;283:4841–4849. doi: 10.1074/jbc.M707822200. [DOI] [PubMed] [Google Scholar]
  • 40.Yu H, Yu H, Karpel R, Chen X. Chemoenzymatic synthesis of CMP-sialic acid derivatives by a one-pot two-enzyme system: comparison of substrate flexibility of three microbial CMP-sialic acid synthetases. Bioorg Med Chem. 2004;12:6427–6435. doi: 10.1016/j.bmc.2004.09.030. [DOI] [PubMed] [Google Scholar]
  • 41.Li Y, Yu H, Cao H, Lau K, Muthana S, Tiwari VK, Son B, Chen X. Pasteurella multocida sialic acid aldolase: a promising biocatalyst. Appl Microbiol Biotechnol. 2008;79:963–970. doi: 10.1007/s00253-008-1506-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Yi W, Liu X, Li Y, Li J, Xia C, Zhou G, Zhang W, Zhao W, Chen X, Wang PG. Remodeling bacterial polysaccharides by metabolic pathway engineering. Proc Natl Acad Sci U S A. 2009;106:4207–4212. doi: 10.1073/pnas.0812432106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kajihara Y, Kamiyama D, Yamamoto N, Sakakibara T, Izumi M, Hashimoto H. Synthesis of 2-[(2-pyridyl)amino]ethyl beta-D-lactosaminide and evaluation of its acceptor ability for sialyltransferase: a comparison with 4-methylumbelliferyl and dansyl beta-D-lactosaminide. Carbohydr Res. 2004;339:1545–1550. doi: 10.1016/j.carres.2004.03.015. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1_si_001

RESOURCES